Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine

International Journal of Oncology

Volumn 37, Issue 5, 2010, Pages 1203-1217

  Fournier, Philippe ^a   Aigner, Maximilian ^a   Schirrmacher, Volker ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b IOZK   (Germany)

Author keywords

Antitumor; Bispecific antibodies; CD28; CD3; Costimulation; Signal 1; Signal 2; T cell activation and proliferation; Vaccination

Indexed keywords

BISPECIFIC ANTIBODY; CD28 ANTIGEN; CD3 ANTIGEN; HYBRID PROTEIN; TUMOR VACCINE; VIRUS HEMAGGLUTININ;

ARTICLE; IMMUNE STATUS; LYMPHOCYTE PROLIFERATION; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY;

ANTIBODIES, BISPECIFIC; ANTIBODIES, VIRAL; ANTIGENS, CD28; ANTIGENS, CD3; CANCER VACCINES; CELL SEPARATION; CROSS-LINKING REAGENTS; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; NEWCASTLE DISEASE VIRUS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 77957868678     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000772     Document Type: Article

References (31)

1. Gilboa E: The makings of a tumor rejection antigen. Immunity 11: 263-270, 1999.
2. Washburn B and Schirrmacher V: Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 21: 85-93, 2002.
3. Schirrmacher V: Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines. Cancer Surv 13: 129-154, 1992.
4. Hicklin DJ, Marincola FM and Ferrone S: HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5: 178-186, 1999.
5. Schlom J and Hodge JW: The diversity of T-cell co-stimulation in the induction of antitumor immunity. Immunol Rev 170: 73-84, 1999. (Pubitemid 29490746)
6. Schirrmacher V, Haas C, Bonifer R and Ertel C: Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res 3: 1135-1148, 1997. (Pubitemid 27319760)
7. Termeer CC, Schirrmacher V, Brocker EB and Becker JC: Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 7: 316-323, 2000. (Pubitemid 30194568)
8. Ertel C, Millar NS, Emmerson PT, Schirrmacher V and von Hoegen P: Viral hemagglutinin augments peptide-specific cytotoxic T cell responses. Eur J Immunol 23: 2592-2596, 1993. (Pubitemid 23295144)
9. Schirrmacher V, Haas, C, Bonifer R, Ahlert T, Gerhards R and Ertel C: Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6: 63-73, 1999. (Pubitemid 29043695)
10. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23: 2439-2453, 2005. (Pubitemid 40332516)
11. Zeng J, Fournier P and Schirrmacher V: High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int J Oncol 25: 293-302, 2004.
12. Haas C, Lulei M, Fournier P, Arnold A and Schirrmacher V: A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Int J Cancer 118: 658-667, 2006. (Pubitemid 43076015)
13. Schirrmacher V: Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 54: 587-598, 2005.
14. Pardoll D: T cells take aim at cancer. Proc Natl Acad Sci USA 99: 15840-15842, 2002.
15. Romagnani S: The Th1/Th2 paradigm. Immunol Today 18: 263-266, 1997.
16. Seliger B, Maeurer MJ and Ferrone S: Antigen-processing machinery breakdown and tumor growth. Immunol Today 21: 455-464, 2000.
17. Willems A, Schoonooghe S, Eeckhout D, De Jaeger G, Grooten J and Mertens N: CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation. Cancer Immunol Immunother 54: 1059-1071, 2005. (Pubitemid 41396811)
18. da Costa L, Renner C, Hartmann F and Pfreundschuh M: Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease. Cancer Chemother Pharmacol 46 (Suppl.): S33-S36, 2000.
19. Doyle SA: Screening for the expression of soluble recombinant protein in Escherichia coli. Methods Mol Biol 310: 115-121, 2005.
20. Hirano A and Wong TC: Generation of mammalian cells expressing stably measles virus proteins via bicistronic RNA. J Virol Methods 33: 135-147, 1991.
21. Kufer P, Zettl F, Borschert K, Lutterbuse R, Kischel R and Riethmuller G: Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun 1: 10, 2001. (Pubitemid 38904405)
22. Kufer P, Lutterbuse R and Baeuerle PA: A revival of bispecific antibodies. Trends Biotechnol 22: 238-244, 2004.
23. Hombach A, Tillmann T, Jensen M, Heuser C, Sircar R, Diehl V, Kruis W and Pohl C: Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Clin Exp Immunol 108: 352-357, 1997.
24. Staerz UD, Kanagawa O and Bevan MJ: Hybrid antibodies can target sites for attack by T cells. Nature 314: 628-631, 1985.
25. Biburger M, Weth R and Wels WS: A novel bispecific tetra-valent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/ HER2. J Mol Biol 346: 1299-1311, 2005.
26. + cells generated from tumorprimed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies. J Immunother 25: 304-313, 2002.
27. Holliger P, Manzke O, Span M, Hawkins R, Fleischmann B, Qinghua L, Wolf J, Diehl V, Cochet O, Winter G and Bohlen H: Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Cancer Res 59: 2909-2916, 1999.
28. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE and Nadler LM: Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 90: 549-561, 1997.
29. Galvin F, Freeman GJ, Razi-Wolf Z, Hall W Jr, Benacerraf B, Nadler L and Reiser H: Murine B7 antigen provides a sufficient costimulatory signal for antigen specific and MHC-restricted T cell activation. J Immunol 149: 3802-3808, 1992.
30. Andres PG, Howland, KC, Dresnek D, Edmondson S, Abbas AK and Krummel MF: CD28 signals in the immature immunological synapse. J Immunol 172: 5880-5886, 2004.
31. Purtic B, Pitcher LA, van Oers NS and Wülfing C: T cell receptor (TCR) clustering in the immunological synapse integrates TCR and costimulatory signaling in selected T cells. Proc Natl Acad Sci USA 102: 2904-2909, 2005. (Pubitemid 40299889)